Octreotide - Aegis Therapeutics

Drug Profile

Octreotide - Aegis Therapeutics

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator Aegis Therapeutics
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acromegaly; Diarrhoea

Most Recent Events

  • 22 Sep 2016 Aegis Therapeutics has patent protection for octreotide (intranasal) in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acromegaly in USA (Intranasal, Spray)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acromegaly in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top